Cabaletta Bio Tests Automated CAR-T Manufacturing in Autoimmune Patients

Cabaletta Bio is set to present initial translational data from the first autoimmune patients treated with rese-cel manufactured via the Cellares Cell Shuttle platform, a fully automated, end-to-end CAR-T production system, at the ASGCT 2026 Annual Meeting in Boston (May 11-15). For GMP-regulated cell therapy manufacturers, the data will test a central question in ATMP scale-up: whether automated platforms can deliver product comparability across donor types without sacrificing process control or regulatory defensibility.

The company will present manufacturing comparability data between healthy donor and autoimmune patient starting material, with findings described as consistent and platform-agnostic. That framing carries direct implications for comparability assessments under ICH Q10 and process validation strategies, particularly as manufacturers weigh platform transitions mid-trial. A separate oral presentation on May 12 will address product quality for resecabtagene autoleucel across starting material sources within the RESET clinical trial program.

Clinical and translational data from the lowest dose cohort of rese-cel administered without lymphodepleting preconditioning in RESET-PV (pemphigus vulgaris) will also be presented. Rese-cel is an investigational autologous CAR-T engineered with a fully human CD19 binder and a 4-1BB co-stimulatory domain, administered as a single weight-based infusion. Eliminating preconditioning, if supported by the data, would reduce patient burden and potentially simplify the site-level logistics that have constrained CAR-T adoption in autoimmune indications outside oncology.

Single-cell profiling of PBMC subsets following rese-cel treatment will be presented across three Phase 1/2 cohorts: RESET-Myositis, RESET-SSc, and RESET-SLE. The breadth of indications under a single manufacturing platform and IND framework raises relevant questions for regulatory affairs teams managing multi-indication development strategies and the associated comparability and bridging study requirements.

All four presentations are scheduled for the ASGCT 2026 Annual Meeting. Presentation materials will be made available on Cabaletta Bio's website following delivery. Abstracts are accessible through the ASGCT 2026 meeting website.